Stay updated with breaking news from Speculative Risk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset Kv7-7000's Phase 3 trial this year, reducing late-stage risks.
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis AG's (NYSE:
Bluebird bio Inc (NASDAQ:BLUE) may have secured FDA approval for its sickle cell disease cell therapy, Lyfgenia, but market reaction has been mixed. Despite...
Here are Friday's biggest calls on Wall Street.
A disappointing Q3 for Plug Power led to four analysts downgrading the stock: "We think it prudent to move to the sidelines."